Edwards Lifesciences (EW) Reports In-Line Q3 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St subdued as markets pause after S&P record high; data, Mideast in focus
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Edwards Lifesciences Reports Third Quarter Results
October 25, 2016 4:15 PM EDTIRVINE, Calif., Oct. 25, 2016 /PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended September 30, 2016.
Third Quarter Highlights:
Sales grew 20.1% to $739.4 million; underlying1 sales were up 18.4% Global Transcatheter Heart Valve Therapy (THVT) sales grew 38.5% U.S. THVT sales were up 55.9% to $259.5 million GAAP EPS was $0.65, an increase of 20.4%; adjusted2 EPS grew 25.9% to $0.68 Reiterated... More